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ABSTRACT
Granulocyte colony-stimulating factor (G-CSF) is an
essential regulator of neutrophil trafﬁcking and is highly
expressed in multiple tumors. Myeloid derived sup-
pressor cells (MDSCs) promote neoplastic progression
through multiple mechanisms by immune suppression.
Despite the ﬁndings of G-CSF function in colon cancer
progression, the precise mechanism of G-CSF on
MDSCs regulation and its blockade effects on tumor
growth remains a worthy area of investigation. In this
study we observed an overexpression of G-CSF in a
mouse colitis-associated cancer (CAC) model, which
was consistent with the accumulation of MDSCs in
mouse colon tissues. Further in vitro studies demon-
strated that G-CSF could promote MDSCs survival and
activation through signal transducer and activator of
transcription 3 (STAT3) signaling pathway. Moreover,
compared with isotype control, anti-G-CSF mAb treat-
ment demonstrated reduced MDSC accumulation, which
led to a marked decrease in neoplasm size and number
in mice. Our results indicated that G-CSF is a critical
regulating molecule in the migration, proliferation and
function maintenance of MDSCs, which could be a
potential therapeutic target for colitis-associated cancer.
KEYWORDS inﬂammation, cancer, granulocyte colony-
stimulating factor, myeloid derived suppressor cells
INTRODUCTION
Colitis-associated cancer (CAC) is a subtype of colorectal
cancer (CRC), which can be originated from inﬂammatory
bowel disease (IBD) (Grivennikov et al., 2012; Candido and
Hagemann, 2013). Preceding chronic inﬂammation is evi-
dent in CAC development, where oxidative stress driven by
pro-inﬂammatory cytokines induces mutations in both
oncogenes and tumor suppressor genes (Vogelstein and
Kinzler, 2004; Wood et al., 2007; Gallimore and Godkin,
2013). The accumulation of mutations in oncogenes and
tumor suppressor genes combined with tumor microenvi-
ronment can ﬁnally lead to tumorigenesis (Wood et al.,
2007).
Myeloid derived suppressor cells (MDSC), a relatively
newly discovered leukocyte population induced in both
cancer patients and animal models, promote neoplastic
progression through multiple mechanisms by immune sup-
pression (Gabrilovich and Nagaraj, 2009; Thevenot et al.,
2014; Condamine et al., 2015). MDSC are found both sys-
temically in the blood and locally at sites of disease (Con-
damine et al., 2015). In mouse models, MDSC subsets can
be divided into monocytic and granulocytic subpopulations
and both have been shown to be equally immunosuppres-
sive (Youn et al., 2008). Monocytic MDSC are designated as
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CD11b+Ly6ChiLy6G− (or CD11b+Gr-1low), whereas granulo-
cytic MDSC as CD11b+Ly6ClowLy6G+ (or CD11b+Gr-1hi)
(Abrams and Waight, 2012; Filipazzi et al., 2012). Activated
MDSC in pathological conditions results in over production of
reactive oxygen species (ROS) and reactive nitric species
(RNS), which abolish T cell mediated cytotoxicity and pro-
mote tumorigenesis (Kusmartsev et al., 2004).
Granulocyte colony-stimulating factor (G-CSF), a well-
known hematopoietic cytokine regulating granulopoiesis, is
an essential regulator to induce neutrophil production as well
as mediate its trafﬁcking from bone marrow to the blood
(Lieschke et al., 1994). G-CSF is also necessary for pro-
genitor cells to differentiate into granulocytic lineage, such as
neutrophils, eosinophils and basophils (Natori et al., 2002).
G-CSF and its receptor G-CSFR were aberrantly expressed
in diverse human tumors, including gastric and colon (Morris
et al., 2014), bladder (Chakraborty and Guha, 2007), pan-
creatic (Liongue et al., 2009), ovarian and cervical cancers
(Savarese et al., 2001). High levels of tumor-associated
G-CSF could promote tumor angiogenesis and metastasis
and correlated with poor patient outcomes (Yokoyama et al.,
2005). In addition, recent studies have demonstrated that
G-CSF could increase proliferation and migration of a subset
of carcinoma cells expressing CD44 (Morris et al., 2014) and
accumulation of granulocytic MDSC in 4T1 mouse breast
tumor model (Waight et al., 2011). Despite the ﬁndings of
G-CSF function in tumor progression, the precise mecha-
nism of G-CSF on MDSC regulation and its blockade effects
on tumor growth remains a worthy area of investigation.
Here, we show that, G-CSF was overexpressed in an
azoxymethane/dextran sodium sulfate (AOM/DSS) treated
mouse CAC model and this overexpression was consistent
with the accumulation of MDSCs in mouse colon tissues.
G-CSF could not only recruit MDSC into inﬂamed colon tis-
sues but also maintained their immature state, promoted
their proliferation and anti-apoptosis abilities. Moreover,
compared with isotype control, anti-G-CSF mAb treated mice
demonstrated reduced MDSC accumulation, which led to
decreased neoplasm size. This study suggested that G-CSF
is a key modulator of MDSC, which might exert a potential
therapeutic target in CAC immunotherapy.
RESULTS
G-CSF expression in colitis-associated colorectal
cancer
Total colonic protein was extracted at stages of AD1 and
AD3 and subsequently subjected to iTRAQ (isobaric Tags for
Relative and Absolute Quantitation). The results showed that
G-CSF was highly expressed by C57-AD compared with
normal C57 mice (Fig. 1). G-CSF was elevated approxi-
mately 47-fold in C57-AD colonic tissues compared with that
in normal C57 mice (see Fig. S1). In addition to the protein-
chip analysis, we further examined the gene and protein
expression of G-CSF in AD and normal mice. We found
extremely high levels of G-CSF production not only in mRNA
level in colon tissue (Fig. 2A) but also in the protein level in
peripheral blood (Fig. 2B). Because a strong inﬂammatory
status was induced in AOM/DSS model, we then examined
the pro-inﬂammatory cytokine proﬁles which might play
important roles in our model by using quantitative real-time
PCR (qRT-PCR). Results showed that IL-6, IL-1β, TNF-α
and Cox-2 mRNA were dramatically over expressed in C57-
AD mice as compared to normal C57 mice. The chemoat-
tractants of CXCL1, CXCL2, CCL2 and CCL7 for recruitment
of neutrophils, MDSCs and macrophages were also
observed to express at substantially elevated levels in C57-
AD colonic tissues (Fig. 2C). These data indicated that
G-CSF is produced at high levels in colitis associated col-
orectal cancer models, and may be a critical player for tumor
progression.
Properties of MDSC in colitis-associated colon tumors
MDSC plays multiple roles in immune responses during
diverse pathological conditions, notably chronic inﬂamma-
tion, infection and neoplasia. Flow cytometry analy-
sis showed that the CD11b+GR-1+ MDSCs in the AD mice
were inﬁltrated much more than that in the normal
mice into the colonic tissues (5.283% ± 0.195% vs.
0.0128% ± 0.0028%, P < 0.001) (Fig. 3A and 3B). Then we
isolated mouse colonic CD11b+GR-1+ MDSCs to determine
the cytokine expression and found that higher expression of
pro-inﬂammatory cytokines, such as IL-6, IL-1β and iNOS as
compared to MDSC from the spleen of normal mice (Fig. 3C
and 3D). This indicated that activated inﬂammatory MDSC in
CAC model may participate in tumor formation by secretion
of pro-inﬂammatory cytokines.
Functional study of MDSCs regulated by G-CSF in vitro
There was a report recognized G-CSF as a pro-inﬂammatory
cytokine which induces the mobilization of hematopoietic
stem cells into the blood (Semerad et al., 1999). Conse-
quently, we proposed that G-CSF in inﬂammatory colonic
tissues might be able to recruit and maintain the function of
bone-marrow derived MDSCs. In order to ascertain this
hypothesis, we therefore isolated the MDSCs and performed
several experiments in vitro. Migration experiment showed
that more MDSCs went through a transwell membrane
toward the media with G-CSF, which indicated that G-CSF
could modulate the movement of MDSCs (Fig. 4A).
Regarding the increased MDSC number in the circulation
and the evidence of chemoattractive capability of G-CSF to
MDSC, we manifested that local G-CSF was released into
the blood, which led to the mobilization of MDSC from bone
marrow and recruitment of the cells to the colon. In vitro
experiments also revealed that G-CSF could maintain
immature status of MDSC, as the cultured bone marrow cells
expressed elevated Gr-1 marker and declined F4/80 marker
(Fig. 4B and 4C). Because Gr-1 was a prominent cell surface
RESEARCH ARTICLE









G-CSF: a key modulator of MDSC and therapeutic target in CAC
131
marker for mouse MDSC differentiation (Li et al., 2004) and
F4/80 was for mouse macrophage differentiation (Gordon
and Taylor, 2005), this ﬂow cytometric analysis demon-
strated that G-CSF could drive bone marrow cells into MDSC
differentiation. Then, we performed the CFSE experiments to
ascertain whether recombinant murine G-CSF could pro-
mote MDSC proliferation and found that MDSC cultured with
IL-4 and rmG-CSF could induce cell proliferation compared
with cells with IL-4 alone (Fig. 4D). Annexin-V PE and PI
anti-apoptosis assay also revealed that G-CSF could induce
the anti-apoptotic effects of MDSC (Fig. 4E). PARP (poly
(ADP-ribose) polymerase) is a substrate of caspase-3 and -7
and its cleavage is one of the well-known markers for the
activation of downstream signals during the apoptosis. We
performed the Western blot analysis and found that the
cleavage of PARP was not seen in G-CSF treated group.
Because signal transducer and activator of transcription 3
(STAT3) could promote MDSCs survival and the activation of
MDSCs, we performed the Western blot analysis and found
that phosphorylated STAT3 was indeed over expressed in
G-CSF stimulated MDSCs (Fig. 4F). Taken together, these
data suggested that local G-CSF not only recruited MDSCs
but also maintained their immature status, activated their
proliferation and anti-apoptosis abilities.
Anti G-CSF therapy reduce MDSC inﬁltration
and cancer formation
The increased G-CSF expression and its stimulatory role in
MDSCs activation prompted us to examine its therapeutic
potential of anti-G-CSF treatment for CRC. After treatment
with anti-G-CSF mAb, MDSC in either colon or peripheral
blood was markedly reduced in comparison with control
animal (Fig. 5A). The protein expression of G-CSF in colonic
tissue was effectively inhibited by anti-mouse G-CSF anti-
body (Fig. 5B). In agreement with the reduction of
MDSCs, the reduced expression of the pro-inﬂammatory
cytokines (iNOS, IL-6, IL-1β) was observed in colon after the
treatment with anti-G-CSF mAb compared to control mice by
IHC. The inﬂammation had been controlled by anti-G-CSF
treatment, which reﬂected in the length of the colon (Fig. 5C).
Furthermore, anti-G-CSF treatment suppressed the tumor
growth with only half detectable tumor node formation in the
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Figure 1. Cytokines produced by colonic tissues from C57-AD and C57-normal mice are compared in a heat map. Color scale
and corresponding cytokine values (pg/mL) are shown.
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MDSC during CAC development. These data indicated that
G-CSF exerted a signiﬁcant impact on pro-tumor function of
MDSC and anti-G-CSF therapy inhibited CAC development.
DISCUSSION
G-CSF, the principal hematopoietic cytokine regulating
granulopoiesis, is widely used for the treatment of neu-
tropenia in a variety of clinical settings. In addition to its
ability to induce neutrophil production, it is now widely
accepted for its function to mobilize neutrophils from bone
marrow to peripheral blood and tissues (Semerad et al.,
2002). MDSCs are a rather heterogeneous subset of mye-
loid cells composed of immature and progenitor cells as well
as mature cells either belonging to the mononuclear or the
polymorphonuclear type (Gabrilovich and Nagaraj, 2009). In
fact, both MDSCs and neutrophils have a common progen-
itor cell and granulocytic MDSCs share many similar fea-
tures with neturophils (Youn et al., 2008). Despite the
regulating function of G-CSF on neutrophils, it has been
largely overlooked for a role in MDSC regulation and the
tumor microenvironment. Our studies demonstrated that
G-CSF has critical roles in MDSCs migration, proliferation
and function maintenance. In addition, we further found that
anti-G-CSF treatment was effective in reducing tumor bur-
den and also inhibiting MDSCs inﬁltration into tumor tissues
in a highly reproducible colitis-associated mouse model. Our
study indicated that G-CSF may be a critical regulating


































































































Figure 2. Detection of G-CSF expression by real-time RT-PCR and ELISA assay in C57-AD and C57 normal mice. (A) G-CSF
mRNA expression in C57 and C57-AD mice. Results are given as fold increase over the mRNA level normalized β-actin and are
representative of at least 3 different experiments; shown are mean ± SD from triplicate values. (B) G-CSF protein expression in
colonic tissues and peripheral blood of C57 and C57-AD mice. The results represent 3 independent experiments (n = 4). (C) Pro-
inﬂammatory and chemoattrants cytokines were analyzed by real-time RT-PCR. Results are given as fold increase over the mRNA
level normalized to β-actin and are representative of at least 3 different experiments; shown are mean ± SD from triplicate values.
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molecule in CAC-associated cancer and could be a potential
therapeutic target.
In mice, MDSCs are characterized by co-expression of
the myeloid-cell lineage differentiation antigen Gr-1 and
CD11b (Li et al., 2004). Normal mouse bone marrow con-
tains 20%–30% of cells with this phenotype, but these cells
make up only a small proportion (2%–4%) of spleen cells
and are absent from the lymph nodes (Bronte et al., 2000).
Our study ascertained that G-CSF could induce the differ-
entiation of bone marrow cells into MDSCs in vitro. This was
in accordance with the ﬁndings from previous studies, which
indicated that treatment of tumor-bearing mice with recom-
binant G-CSF could induce the accumulation of MDSCs
in vivo (Waight et al., 2011). In addition, the transwell
migration assay of our experiment also demonstrated that
G-CSF could mobilize MDSC and this indicated that G-CSF
may be one of various cytokines in recruiting MDSCs from
bone marrow to peripheral blood. In addition to G-CSF in
MDSC recruitment from bone marrow, other studies have
also demonstrated that chemokines CXCL1 and CXCL2
could promote the recruitment of MDSCs to the spleen
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Figure 3. Inﬁltration of MDSCs into the colonic tissues and its pro-inﬂammatory properities. (A) Flow cytometry dot plot gating
for MDSCs (CD11b+Gr-1+) inﬁltration into colon tissues along the disease development. The results represent 3 independent
experiments (n = 4). (B) Statistical analysis of inﬁltrated MDSCs in the colonic tissues of C57 normal and AD mice. The results
represent 3 independent experiments (n = 6). * represents P < 0.05; P values were obtained using two-tailed Student’s t tests.
(C) Fluorescence-activated cell sorting of MDSCs in C57-AD mice colonic tissues and spleen of C57 mice. The left was sorted
MDSCs from spleen of C57 mice and the right was sorted MDSCs from colonic tissues of C57-AD mice. (D) Total RNA from MDSCs
sorted from C57 normal and C57-AD mice were analyzed by real-time RT-PCR for the expression of pro-inﬂammatory cytokines.
Results are given as fold increase over the mRNA level normalized to β-actin and are representative of at least 3 different
experiments; shown are mean ± SD from triplicate values.
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2010). Another cytokine stimulating factor, granulocyte-
macrophage CSF (GM-CSF), exerts an important role in
splenic recruitment of MDSCs in tumor bearing-mice (Bayne
et al., 2012). In addition to MDSCs recruitment, G-CSF could
also maintain MDSCs immature properities and promote its
proliferation and anti-apoptosis abilities. Waight J.D, et al.
has also demonstrated that G-CSF protein alone was sufﬁ-
cient to generate granulocytic-like MDSC, which strongly
recapitulated phenotypic, functional and molecular charac-
teristics observed with tumor-induced granulocytic MDSC
(Waight et al., 2011).
Another existing ﬁnding of our study revealed that MDSC
isolated from AOM/DSS mice could secret pro-inﬂammatory
cytokines, such as IL-6, IL-1β and iNOS. IL-6, an important
pro-inﬂammatory cytokines in infection and tumor, could
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Figure 4. In vitro study of MDSC regulated by G-CSF. (A) The in vitro study of MDSC recruited by G-CSF. MDSCs isolated from
bone marrow went through a transwell membrane toward the media with IL-4 alone or IL-4/G-CSF combination for 4 h. (B–C) MDSCs
isolated from bone marrow were cultured with IL-4 alone or the combination of IL-4/G-CSF for 6 days. Flow cytometric analysis of Gr-
1 and F4/80 markers expressed in the cell surface of MDSCs. (D) CFSE proliferation assay. MDSCs isolated from bone marrow were
incubated with CFSE previously, and then cultured with IL-4 lone or IL-4/G-CSF combination for 6 days. (E) MDSCs cultured with IL-4
lone or IL-4/G-CSF combination for 6 days, and then the apoptotic fraction was determined by using Annexin V-PE and PI
ﬂuorescences measured by a ﬂow cytometer. (F) Western blot detection of pSTAT3 in G-CSF activated MDSCs. Equal loading is
visualized by β-actin expression.
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et al., 2007). Previous studies have also shown that IL-6
could trigger signaling pathways in MDSCs that converge on
signal transducer and activator of transcription 3 (STAT3)
(Kortylewski et al., 2005; Nefedova et al., 2005). These
transcription factors promote survival and activation of
MDSCs, which leads to the upregulation of arginase 1 and
inducible nitric oxide synthase (iNOS) (Kusmartsev et al.,
2004). Our studies have also indicated the activation of
MDSCs by protein expression of phosphorylate STAT3.
Several other reports also demonstrated that G-CSF
expression in various solid tumors could promote tumor
growth and metastasis (Morris et al., 2014). Consequently,
through G-CSF blockade, we found that anti-G-CSF treat-
ment suppressed the tumor growth as well as reduced
inﬁltration of MDSCs in the colon. This was in accordance
with previous ﬁndings that anti-G-CSF treatments appear to
be very effective at reducing the number and size of neo-
plasms in the AOM/DSS mouse model of CRC (Morris et al.,
2015). Once G-CSF was blockaded, both the MDSCs inﬁl-
tration and the expression of pro-inﬂammatory cytokines
were markedly reduced in either colon or peripheral blood.
Taken together, our ﬁndings provide evidence that G-CSF
has critical roles in MDSCs migration, proliferation and
function maintenance. In vitro studies have also demon-
strated that G-CSF could promote survival and activation of
MDSCs through STAT3 signaling pathway. In addition, anti-
G-CSF treatment suppressed the tumor growth as well as
reduced inﬁltration of MDSCs in the AOM/DSS mouse model
of CRC. Our results indicated that G-CSF may be a critical




Azoxymethane (AOM, MW: 74) and Dextran sodium sulfate (DSS,
MW: 36,000–50,000) were purchased from Sigma-Aldrich and MP
Biochemicals Inc. USA, respectively. Pathogen free 8–10 week old
female wild type C57/BL6 mice and SCID mice with a C57/BL6
genetic background, were housed under speciﬁc pathogen free
conditions with free access to food and water during the course of
experiments. Mice were injected with a single intraperitoneal
administration of AOM dissolved in physiological saline with a dose
of 12.5 mg/kg body weight. Ten days later, 2.5% DSS water was
given in the drinking water for 5 days, followed by 14 days of regular
water. Mice were treated with 3 cycles of DSS water. At each end
point of DSS water, mice fed with DSS water were deﬁned as AD1,
AD2 and AD3, respectively. Body weight was measured every week,
and the animals were sacriﬁced at the indicated time intervals for
macroscopic inspection, histological analysis, and total RNA
extraction.
Protein-chip assay
Colon tissues protein chip of cytokines and chemokines were tested
by Ray-Biotech mouse protein array QAM-INT-1-2 (Capital Bio,
Beijing, China) and QAM-CHE-1-2 (Capital Bio, Beijing, China)
respectively. Brieﬂy, the printed chips were blocked with 30 μL
blocking solution (PBS containing 5% w/v non-fat milk)/well for 1 h at
room temperature. After that, standard protein, blank control and
serum samples were added in different wells for 45 min at room
temperature followed by 1-h incubation with detection antibody.
Finally, diluted streptavidin-Cy3 (Sigma, Missouri, USA) was added
for 1 h incubation at room temperature. Extensive washing with
0.05% PBS-Tween 20 followed each incubation step to reduce
nonspeciﬁc binding. The chip images were obtained by LuxScanTM
10 K Microarray Scanner (CapitalBio, Beijing, China) using Cy3
settings. The scannerhe scanner Cy3 settings. TLuxScan 3.0.0720,
was used to quantify the spot ﬂuorescence intensity from the
scanned images.
Immune cell isolation
Immune cells were isolated from colon tissues, peripheral blood,
bone marrow and spleen by ﬂow sorting. Single-cell suspensions
from colon tissue dissection were prepared by manual mincing using
scalpel followed by enzymatic digestion for 40 min at 37°C by Col-
lagenase A 2.0 mg/mL (Roche, Canada) and DNase I 100U/mL
(Roche, Canada) dissolved in DMEM (Gibco, USA) under continu-
ous stirring. Digestion mixtures were resuspended by DMEM con-
taining 10% FBS and then ﬁltered through 70 μm nylon strainers
(Falcon, BD biosciences, USA). Immune cells from peripheral blood,
bone marrow and spleen were obtained by Ficoll-Hypaque (TBD
science, China) density centrifugation 2000 rpm for 20 min.
Flow cytometric analysis
Cells were incubated for 10 min at 4°C with rat anti-mouse CD16/
CD32 mAb (1:200, Quantobio, China) at a 1:100 dilution in PBS
containing 2% of FBS (Sigma, USA) to prevent nonspeciﬁc antibody
binding. Subsequently, cells were washed twice in PBS/FBS and
incubated for 30 min with 100 μL of each of the following ﬂuo-
rophore-conjugated anti-mouse antibodies: CD11b-APC (M1/70),
CD19-APC (MB19-1), CD45-PE-cy7 (30-F11), F4/80-PE (BM8) and
Gr-1-FITC (RB6-8C5) (all from eBioscience, USA). Antibodies were
used at 1:100 dilution in PBS containing 2% FBS. Data acquisition
was performed on a FACS Calibur using CellQuestPro software (BD
Biosciences, USA) and analysis carried out using FlowJo software
program (Tree Star Inc, USA).
Quantitative real time PCR
Total RNA was extracted from 500,000 FACS sorted
CD45+CD11b+Gr1+ cells by using an RNeasy Mini Kit (Qiagen). The
cDNAs were synthesized by using Superscript III First-Strand Syn-
thesis (Invitrogen). Primers speciﬁc for β-actin, IL-6, G-CSF, NOS2,
IL-1β (Invitrogen) were used and relative gene expression deter-
mined by using RT Real-Time SYBR Green/ROX PCR master mix
(Takara, Japan) on an LightCycler 480 quantitative PCR machine
(Roche). The comparative threshold cycle method was employed to
calculate the changes in gene expression, which was normalized to
both β-actin as reference genes. Samples were assayed from at
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least three independent experiments per category. The primers of
genes were listed below:
ELISA assay
Various G-CSF concentrations with conditioned medium were
assayed by using Ready-Set-Go ELISA kit (R&D systems) as
described by the manufacturer. Optical density was measured at
450 nm with wavelength correction set to 540 nm on a SpectraMax
340 spectrophotomoter (Molecular Devices).
MDSC migration assay
MDSCs were obtained by ﬂow cytometric sorting. MDSCs were
washed with PBS twice and resuspended with 5 × 105/mL in a
DMEM with 10% FBS, 10 ng/mL rmIL-4 (Peprotech, USA). Transwell
chambers (Corning, USA) were placed in a 24-well plate, the lower
chamber was ﬁlled with DMEM with 10% FBS, 10 ng/mL rmIL-4 with/
without 100 ng/mL rmG-CSF (Peprotech, USA), and the upper
chamber was ﬁlled with MDSCs. After 4 h, cells were harvested in
the lower chamber and counted by the cells counts.
Bone marrow cells proliferation assay
Cells were resuspended at 1∼2 × 106/mL in a minimum volume of
1 mL PBS and incubated with carboxyﬂuorescein succinimidyl
amino ester (CFSE, 5 mmol/L) at 37°C for 10 min with constant
swirling. The reaction was then quenched with media containing
10% FCS, washed with PBS for two times. Cells labeled with CFSE
were cultured in 96-well plates (1 × 105 cells/well) and stimulated
with 100 ng/mL G-CSF plus 10 ng/mL IL-4 or 10 ng/mL IL-4 alone,
respectively. After incubation for 6 days, cells were harvested and
analyzed by using FACS Calibur (BD).
Cell apoptotic assay
Bone marrow cells were cultured with 100 ng/mL G-CSF plus
10 ng/mL IL-4 or 10 ng/mL IL-4 alone, respectively. After 6 days,
cells were harvested and tested for apoptosis. The apoptotic fraction
was determined by using Annexin V-PE apoptosis kit (Sounthern
Biotech, Birmingherm, AL, USA) for 15 min at 4°C in dark in
accordance with the manufacturer’s instructions, followed by adding
with Propidine iodide (PI). Annexin-V PE and PI ﬂuorescences were
measured by using a ﬂow cytometer.
Western blot analysis
Cells were lysed in 1× SDS-PAGE sample buffer, and the total
protein was quantiﬁed using the BCA protein assay reagent (Thermo
Fisher, Grand Island, NY, USA). The cell lysates were loaded onto a
10% SDS-PAGE gel and separated and then electrophoretically
transferred to a polyvinylidene ﬂuoride membrane. The membrane
was blocked in a 5% skim milk suspension for 1 h at room tem-
perature prior to an overnight incubation at 4°C with one of the
following primary antibodies: anti-poly (ADP-ribose) polymerase
(PARP) (9542, Cell Signaling Technology, Danvers, MA, USA), anti-
phospho-Stat3 (Tyr 705) (D3A7, Cell Signaling Technology, Dan-
vers, MA, USA). The membrane was blocked in a 5% skim milk
suspension for 1 h at room temperature prior to an overnight incu-
bation at SA), anti-phospho-Stat3 (Tyr 705) (D3A7, Cell Signaling
Technology, Danvers, MA, USA). The membrane was subsequently
incubated with the anti-rabbit or anti-mouse HRP-IgG (Santa Cruz
Biotechnology) secondary antibody for 1 h at room temperature.
Chemiluminescence was detected with an ECL blot detection sys-
tem (Santa Cruz Biotechnology).
G-CSF treatment
Pathogen free 8- to 10-week old female WT C57/BL6 mice and
SCID mice on a C57/BL6 genetic background, were housed under
speciﬁc pathogen-free conditions with free access to food and water
during the course of experiments. Mice were injected with a single
intraperitoneal administration of AOM dissolved in physiological
saline of a dose of 12.5 mg/kg body weight. Ten days later, 2.5%
DSS water was given in the drinking water for 5 days, followed by
Figure 5. Anti-G-CSF treatment reduces MDSC inﬁltration
and cancer formation. (A) The percentage of MDSCs in the
colon or peripheral blood of anti-G-CSF mAb treated mice
compared with control animal measured by ﬂow cytometry. The
results represent 3 independent experiments (n = 8). (B) The
appearance of colon from wild type mice, AD3 mice treated with
anti-G-CSF mAb, AD3 mice treated with rabbit IgG and control
mice (from top to bottom) (up). The length of colon from the four
groups mentioned above (from left to right) (middle). Number of
colonic tumor node from AD3 mice treated with anti-G-CSF
mAb, AD3 mice treated with rabbit IgG and control mice (from
left to right) (below). The results represent 3 independent
experiments (n = 3). * represents P < 0.05; P values were
obtained using two-tailed Student's t tests. (C) The pro-
inﬂammatory cytokine iNOS (up), IL-6 (middle), IL-1β (below)-
expression in colon after treatment with anti-G-CSF mAb (right)
compared to control mice (left) by IHC. The results represent 3
independent experiments (n = 3).
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14 days of regular water. Mice were treated with 3 cycles of DSS
water. G-CSF was neutralized through IV injection at a dose of
10 mg/kg of G-CSF mAb (Cat No. 500-P69, Peprotech) 1 h before
each DSS feeding. Mice were sacriﬁced at AD1 and AD3. Bone
marrows, spleens, peripheral blood, colon tissues were collected
and measured as described previously.
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